PMID- 32166618
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1573-7403 (Electronic)
IS  - 1386-341X (Linking)
VI  - 23
IP  - 4
DP  - 2020 Aug
TI  - Cardiovascular effects of growth hormone (GH) treatment on GH-deficient adults: a 
      meta-analysis update.
PG  - 467-475
LID - 10.1007/s11102-020-01036-0 [doi]
AB  - BACKGROUND: It is still unclear whether growth hormone (GH) replacement is able 
      to improve cardiovascular parameters in adults with GH deficiency (AGHD) from the 
      updated clinical trials reported to date. METHODS AND RESULTS: We systematically 
      reviewed clinical trials of GH treatment on AGHD patients in recent decade, and 
      evaluated the effects of GH on cardiovascular parameters assessed by 
      echocardiography. 11 clinical trials were identified in 3 bibliographic 
      databases. We conducted a combined analysis of effects on four aspects: General 
      indicators: baseline heart rate (BHR), peak heart rate (PHR), systolic blood 
      pressure (SBP), diastolic blood pressure (DBP); Cardiac structure: left 
      ventricular end diastolic volume (LVEDV), left ventricular end systolic volume 
      (LVESV), left ventricular interventricular septum (LVIS), left ventricular mass 
      (LVM), left ventricular posterior wall (LVPW); Cardiovascular function: 
      deceleration time of E wave (DT), E/A ratio (E/A), ejection fraction (EF), 
      NT-BNP; Life quality: peak VO(2), VE/VCO(2) slope. Overall effect size was used 
      to evaluate significance, and weighted mean difference after GH treatment was 
      given to appreciate size of the effect. GH treatment was associated with a 
      significant increase in BHR (3.03[2.00, 4.06]), LVIS (0.50[0.43, 0.57]), LVPW 
      (0.50[0.43, 0.57]), and EF (2.12[1.34, 2.90]). Overall effect sizes were negative 
      significant for DBP (- 1.19[- 2.33, - 0.05]), LVEDV (- 9.84[- 16.53, - 3.15]), 
      NT-BNP (- 206.34[- 308.95, - 103.72]), and VE/VCO2 slope 
      (- 2.31[- 2.92, - 1.71]). CONCLUSIONS: As assessed by echocardiography, GH 
      administration may improve the general vital signs and life quality of AGHD 
      patients, based on the positive effect on BHR and negative effects on DBP and 
      VE/VCO(2) slope. Also, GH treatment would influence the structure of heart with 
      positive effects on LVIS, LVPW and negative effect on LVEDV, which together with 
      the increase of EF and decrease of NT-BNP, then resulting in improving the 
      systolic function of AGHD patients.
FAU - Zhang, Siwen
AU  - Zhang S
AD  - Department of Endocrinology and Metabolism, The First Hospital of Jilin 
      University, NO.71 Xinmin Street, 130021, Changchun, Jilin, People's Republic of 
      China.
FAU - Li, Zhuo
AU  - Li Z
AD  - Department of Endocrinology and Metabolism, The First Hospital of Jilin 
      University, NO.71 Xinmin Street, 130021, Changchun, Jilin, People's Republic of 
      China.
FAU - Lv, You
AU  - Lv Y
AD  - Department of Endocrinology and Metabolism, The First Hospital of Jilin 
      University, NO.71 Xinmin Street, 130021, Changchun, Jilin, People's Republic of 
      China.
FAU - Sun, Lin
AU  - Sun L
AD  - Department of Endocrinology and Metabolism, The First Hospital of Jilin 
      University, NO.71 Xinmin Street, 130021, Changchun, Jilin, People's Republic of 
      China.
FAU - Xiao, Xianchao
AU  - Xiao X
AD  - Department of Endocrinology and Metabolism, The First Hospital of Jilin 
      University, NO.71 Xinmin Street, 130021, Changchun, Jilin, People's Republic of 
      China.
FAU - Gang, Xiaokun
AU  - Gang X
AD  - Department of Endocrinology and Metabolism, The First Hospital of Jilin 
      University, NO.71 Xinmin Street, 130021, Changchun, Jilin, People's Republic of 
      China. insightful@126.com.
FAU - Wang, Guixia
AU  - Wang G
AD  - Department of Endocrinology and Metabolism, The First Hospital of Jilin 
      University, NO.71 Xinmin Street, 130021, Changchun, Jilin, People's Republic of 
      China. gwang168@jlu.edu.cn.
LA  - eng
GR  - JDYY92018039/Youth Development Fund of the First Hospital of Jilin University/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Pituitary
JT  - Pituitary
JID - 9814578
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 12629-01-5 (Human Growth Hormone)
SB  - IM
MH  - Adult
MH  - Blood Pressure/physiology
MH  - Echocardiography
MH  - Heart Disease Risk Factors
MH  - Heart Rate/physiology
MH  - Heart Ventricles/diagnostic imaging/pathology
MH  - *Hormone Replacement Therapy
MH  - Human Growth Hormone/*deficiency/*therapeutic use
MH  - Humans
MH  - Hypopituitarism/blood/diagnostic imaging/*drug therapy/physiopathology
MH  - Natriuretic Peptide, Brain/blood
MH  - Organ Size
MH  - Oxygen Consumption/physiology
MH  - Peptide Fragments/blood
MH  - Recombinant Proteins
MH  - Stroke Volume/physiology
MH  - Ventricular Remodeling/physiology
MH  - Ventricular Septum/diagnostic imaging/pathology
OTO - NOTNLM
OT  - Cardiac structure
OT  - Cardiovascular function
OT  - Echocardiography
OT  - GH treatment
OT  - Growth hormone deficiency
EDAT- 2020/03/14 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/03/14 06:00
PHST- 2020/03/14 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PHST- 2020/03/14 06:00 [entrez]
AID - 10.1007/s11102-020-01036-0 [pii]
AID - 10.1007/s11102-020-01036-0 [doi]
PST - ppublish
SO  - Pituitary. 2020 Aug;23(4):467-475. doi: 10.1007/s11102-020-01036-0.